These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 34337520)
1. Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer. Wagaskar VG; Levy M; Ratnani P; Moody K; Garcia M; Pedraza AM; Parekh S; Pandav K; Shukla B; Prasad S; Sobotka S; Haines K; Punnen S; Wiklund P; Tewari A Eur Urol Open Sci; 2021 Jun; 28():9-16. PubMed ID: 34337520 [TBL] [Abstract][Full Text] [Related]
2. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer. Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541 [TBL] [Abstract][Full Text] [Related]
3. Development and External Validation of a Prediction Model to Identify Candidates for Prostate Biopsy. Wagaskar VG; Lantz A; Sobotka S; Ratnani P; Parekh S; Falagario UG; Li L; Lewis S; Haines Iii K; Punnen S; Wiklund P; Tewari A Urol J; 2022 Nov; 19(5):379-385. PubMed ID: 34978065 [TBL] [Abstract][Full Text] [Related]
4. The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator. Parekh S; Ratnani P; Falagario U; Lundon D; Kewlani D; Nasri J; Dovey Z; Stroumbakis D; Ranti D; Grauer R; Sobotka S; Pedraza A; Wagaskar V; Mistry L; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Martini A; Picker W; Haug E; Cormio L; Nordström T; Briganti A; Boström PJ; Carrieri G; Haines K; Gorin MA; Wiklund P; Menon M; Tewari A Eur Urol Open Sci; 2022 Jul; 41():45-54. PubMed ID: 35813258 [TBL] [Abstract][Full Text] [Related]
5. Nomogram predicting prostate cancer in patients with negative prebiopsy multiparametric magnetic resonance. Chen M; Wang R; Zhang T; Zhang X; Wan Y; Fu X Future Oncol; 2022 Apr; 18(12):1473-1483. PubMed ID: 35105154 [TBL] [Abstract][Full Text] [Related]
6. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region. Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557 [TBL] [Abstract][Full Text] [Related]
7. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next? Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957 [TBL] [Abstract][Full Text] [Related]
8. The "Is mpMRI Enough" or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy. Stonier T; Simson N; Shah T; Lobo N; Amer T; Lee SM; Bass E; Chau E; Grey A; McCartan N; Acher P; Ahmad I; Arumainayagam N; Brown D; Chapman A; Elf D; Hartington T; Ibrahim I; Leung H; Liyanage S; Lovegrove C; Malthouse T; Mateen B; Mistry K; Morrison I; Nalagatla S; Persad R; Pope A; Sokhi H; Syed H; Tadtayev S; Tharmaratnam M; Qteishat A; Miah S; Emberton M; Moore C; Walton T; Eddy B; Ahmed HU Eur Urol Focus; 2021 Sep; 7(5):1027-1034. PubMed ID: 33046412 [TBL] [Abstract][Full Text] [Related]
9. Assessing the Role of High-resolution Microultrasound Among Naïve Patients with Negative Multiparametric Magnetic Resonance Imaging and a Persistently High Suspicion of Prostate Cancer. Avolio PP; Lughezzani G; Fasulo V; Maffei D; Sanchez-Salas R; Paciotti M; Saitta C; De Carne F; Saita A; Hurle R; Lazzeri M; Guazzoni G; Buffi NM; Casale P Eur Urol Open Sci; 2023 Jan; 47():73-79. PubMed ID: 36601049 [TBL] [Abstract][Full Text] [Related]
10. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions. Fang AM; Shumaker LA; Martin KD; Jackson JC; Fan RE; Khajir G; Patel HD; Soodana-Prakash N; Vourganti S; Filson CP; Sonn GA; Sprenkle PC; Gupta GN; Punnen S; Rais-Bahrami S Cancer; 2022 Sep; 128(18):3287-3296. PubMed ID: 35819253 [TBL] [Abstract][Full Text] [Related]
11. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score. Pellegrino F; Stabile A; Sorce G; Quarta L; Robesti D; Cannoletta D; Cirulli G; Barletta F; Scuderi S; Mazzone E; de Angelis M; Brembilla G; De Cobelli F; Salonia A; Montorsi F; Briganti A; Gandaglia G Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37865591 [TBL] [Abstract][Full Text] [Related]
12. Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer. Stabile A; Dell'Oglio P; Soligo M; De Cobelli F; Gandaglia G; Fossati N; Esposito A; Brembilla G; Karnes RJ; Montorsi F; Briganti A Eur Urol Oncol; 2021 Aug; 4(4):594-600. PubMed ID: 31204312 [TBL] [Abstract][Full Text] [Related]
13. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3? Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884 [TBL] [Abstract][Full Text] [Related]
14. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy. Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D Eur Urol Open Sci; 2023 Jul; 53():90-97. PubMed ID: 37441340 [TBL] [Abstract][Full Text] [Related]
15. Multivariable Models Incorporating Multiparametric Magnetic Resonance Imaging Efficiently Predict Results of Prostate Biopsy and Reduce Unnecessary Biopsy. Yu S; Hong G; Tao J; Shen Y; Liu J; Dong B; Fan Y; Li Z; Zhu A; Zhang X Front Oncol; 2020; 10():575261. PubMed ID: 33262944 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic Accuracy of Microultrasound in Patients with a Suspicion of Prostate Cancer at Magnetic Resonance Imaging: A Single-institutional Prospective Study. Lughezzani G; Maffei D; Saita A; Paciotti M; Diana P; Buffi NM; Colombo P; Elefante GM; Hurle R; Lazzeri M; Guazzoni G; Casale P Eur Urol Focus; 2021 Sep; 7(5):1019-1026. PubMed ID: 33069624 [TBL] [Abstract][Full Text] [Related]
17. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981 [TBL] [Abstract][Full Text] [Related]
18. MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy. Huang C; Song G; Wang H; Ji G; Li J; Chen Y; Fan Y; Fang D; Xiong G; Xin Z; Zhou L Biomed Res Int; 2018; 2018():6368309. PubMed ID: 30276213 [TBL] [Abstract][Full Text] [Related]
19. There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies. Dell'Oglio P; Stabile A; Soligo M; Brembilla G; Esposito A; Gandaglia G; Fossati N; Bravi CA; Dehò F; De Cobelli F; Montorsi F; Karnes RJ; Briganti A Eur Urol Oncol; 2020 Feb; 3(1):112-118. PubMed ID: 31411973 [TBL] [Abstract][Full Text] [Related]
20. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics. Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]